We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 10.25 | 44.09% | 33.50 | 5,873,998 | 16:28:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 33.00 | 34.00 | 33.75 | 23.75 | 23.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -3.19M | -0.0469 | -7.14 | 22.8M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:30:00 | O | 50,000 | 31.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/4/2024 | 07:00 | UK RNS | Sareum Holdings PLC Final Issue of RiverFort Subscription Shares |
| 19/4/2024 | 12:16 | ALNC |  IN BRIEF: Sareum falls as issues shares to RiverFort Global |
| 19/4/2024 | 11:35 | UK RNS | Sareum Holdings PLC Issue of RiverFort Subscription Shares |
| 15/4/2024 | 15:28 | UK RNS | Sareum Holdings PLC Issue of RiverFort Subscription Shares |
| 09/4/2024 | 16:00 | UK RNS | Sareum Holdings PLC Issue of RiverFort Subscription Shares |
| 04/4/2024 | 17:24 | ALNC | TRADING UPDATES: Northcoders launches bootcamp; Schroder invests |
| 04/4/2024 | 14:38 | UK RNS | Sareum Holdings PLC Completion of Equity Fundraise |
| 02/4/2024 | 17:35 | ALNC | TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec |
| 02/4/2024 | 16:51 | UK RNS | Sareum Holdings PLC Result of WRAP Retail Offer |
| 02/4/2024 | 07:00 | UK RNS | Sareum Holdings PLC Increase in size of WRAP Retail Offer |
Sareum (SAR) Share Charts1 Year Sareum Chart |
|
1 Month Sareum Chart |
Intraday Sareum Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/4/2024 | 23:40 | Sareum 2015 | 16,483 |
| 28/11/2022 | 20:37 | SRA737 | 16 |
| 05/8/2021 | 08:49 | No more rns until current project closed | - |
| 04/7/2021 | 20:52 | SAR 2013 , SHORT THE ARSE OUT OF IT THREAD | 326 |
| 08/1/2021 | 18:09 | SAR - Sareum Holdings drug discovery | 370 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-23 16:07:36 | 31.80 | 50,000 | 15,900.00 | O |
| 2024-04-23 15:53:02 | 30.44 | 49,234 | 14,986.83 | O |
| 2024-04-23 15:30:01 | 34.00 | 1,455 | 494.70 | O |
| 2024-04-23 15:29:55 | 33.38 | 30,000 | 10,012.50 | O |
| 2024-04-23 15:29:53 | 34.00 | 2,177 | 740.18 | O |
| Top Posts |
|---|
Posted at 23/4/2024 18:26 by wolfofwallstreets Great post on LSE..I believe that the BOD, while negligent, they did shape up when heel come to shove in organising the recent funding arrangement.... HAHAH So..the BOD enter into a disastrous funding arrangement with RF which destroys the share price.. After doing so...they run out of cash.. needing to sell more shares to happy clappy investors to raise cash... Dilution is now horrendous... But the share price has had a nice wee bounce.. So never mind the destruction of .market cap...dilution..poor decisions.. The share price has risen! So now we all love the BOD! Until..you know..the next problem... |
Posted at 15/4/2024 11:50 by peaceandlove Of course the silver grey lady (see below) top sliced in 2021 🤣😆 PMSL at all you happy clappers who top sliced in June 2021 when the share price was at 9p. At the time everyone was holding for 28p - the month of rerate. Now you've all top sliced. In June 2021, Trimme told you to top slice and he was bullied into submission. No shame from you nasty people!This little spike in the share price is predictable, as are all the happy clappers starting to shout £5 would be nice or even £2.50 per share. Shows me and everyone what uneducated fools you all are! 😆 A big dump coming, mark this post. Now I will explain yet again why I feel this is a bad investment. But you happy clappers have to at least put up one shed of evidence that shows this company will succeed? No 'If's or What ifs' Actual evidence, that is factual! The Clinical Trial is a phase 1 protocol. This assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. The MHRA refused Sareum a Phase 1 CTA (Clinical Trial Authorisation) despite the fact that an external & experienced Consultancy (CRO) had developed the novel capsule technology for them. I suspect the MHRA may have felt that the novel formulation was not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the clinical trial. By going to the Australian Regulator Authority Sareum hopes to use their diminishing financial resources to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b). In addition, Sareum will have to go back to investors to raise more money. This is not good and could result in more dilution of your share holding. I leave it to your imagination as to the struggle Sareum will have if the Phase 1 outcome is unfavourable. Horrid, you come across as extremely inexperienced and naive to say you've been making money on this stock. You wouldn't be holding a single share here if you were experienced, the fact you do and you're underwater tells everyone that you're not. PMSL at you the most, you're such a prat! Silverfoil13 Posts: 1,561 Price: 16.00 No Opinion RE: Some taking profits on their 10p buysToday 11:11 Like you Mitty I got in in 2011 after the excitement of the mice trials .. sold 1/3 in July 2021 .. then topped up 2 weeks ago at 10p so hold more now than before but at a much lower average. A share price above £1 now would represent a sound investment anything above £2.50 would be brilliant anything above £5 would be stunning 🙄 You couldn't make it up. Market cap of £16million. The MCAP has gone up £6million in 2 weeks and the happy clappers are now talking a MCAP £492,895,545 from £16million. LMFAO at these muppets! |
Posted at 07/4/2024 21:24 by peaceandlove Wolf, the rampers are on a different planet to me. Sareum's current market value is correct, £8million based on the following.1) No revenue. 2) Dilution with more on the cards. 3) As you say 737 was turned down by GSK. 4) None of Sareum's products are proven. 5) Phase 1 of the clinical trial is safety only. 6) The MHRA turned Sareum down for a clinical trial in the UK. This is an enormous red flag for me. 7) Board are still taking large salaries as 'working capital'. 8) It almost 20 years since Sareum were listed on AIM. 20 years and the share price 92% down. 9) No license deals even though Sareum's business model is to license pre clinical or early on in the clinical trial. To be frank, Sareum have had 20 years and produced f all. What does that tell you?????? Oh yeah this is the year of rerate, the year of license deals, the year of 1801, the year of 737, the year of revenue. Come on Sar.... 😆🤣 |
Posted at 04/4/2024 16:47 by peaceandlove Hi Mike, I will give you my opinion, but as you say, the rampers will jump all over me. Horrid Henry is Horrid by name and horrid by nature.Firstly, you've to ask yourself, why the share price has fallen 83% YTD even with todays slight increase in value. The rampers will tell you it's the board's fault because of 'death spiral' finance, but I feel it's much more than that. I have spent a longtime reviewing Sareum and note the following. The Clinical Trial is a phase 1 protocol. This assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. The MHRA refused Sareum a Phase 1 CTA (Clinical Trial Authorisation) despite the fact that an external & experienced Consultancy (CRO) had developed the novel capsule technology for them. I suspect the MHRA may feel that the novel formulation is not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the clinical trial. By going to the Australian Regulator Authority, Sareum is hoping to use their diminishing financial resources to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b). In addition to all of the above, the company admits that to go forward through and beyond the Phase 1 trial, it will have to go back to investors to raise more money. This is not good and could result in more dilution of your share holding. I leave it to your imagination as to the struggle Sareum will have if the Phase 1 outcome is unfavourable. Sorry I can’t be more positive but suffice to say this looks to me like the last throw of the dice for Sareum. I hope this helps. |
Posted at 03/4/2024 08:53 by peaceandlove Good morning,At present the market doesn't think Sareum will ever be able to license their products. If something is highly likely to happen then this would already be built into the share price. The 10p share price (new money) currently suggests to me the market believes Sareum license deals are very unlikely to happen. Hence why the rampers believe if it does happen there will be a violent rerate. Rampers are betting against the market knowing better, which doesn't bode well. Most of the rampers do not know what they're talking about and offer nothing in regard to evidence of their claims that this is the best thing since sliced bread. The SOG's and Horrid's of this world are dreamers. Most probably wanting to retire because of mundane jobs. Most HNWIs wouldn't invest in a company like Sareum, so when Horrid is talking about beers in the sunshine or going to F1 events he is clearly dreaming like the rest of the rampers hoping that one day his so called golden tickets come in. |
Posted at 02/4/2024 21:24 by peaceandlove To be fair to Num4, it is a decent post. It's certainly fairer than the dross SOG and Laz put up.Unfortunately, for me though, it's too optimistic. Even with safety data, 1801 hasn't enticed any pharmaceutical companies. Why is that? Sareum have always want to license pre clinical or early clinical trial. In addition, the MHRA had their reasons for not authorising the clinical trial in the UK. That in itself is a massive red flag. For me Sareum is now taking advantage of shareholders hoping that this company will change their lives - total fantasy. It's up to them, but Sareum now know they can go to them for money. This could potentially drag on for years. I reckon the share price will continue to be diluted, coupled with no revenue, losses that will have increase and more importantly than anything else I do not think their products will be licensed. The share price will continue to fall. |
Posted at 02/4/2024 08:19 by peaceandlove Good morning, nothing has changed - LSE happy clappers yet again putting all their faith into a company that as you said needs all the money they can get. Comments like this one;"As expected, SAR's army of small investors are giving a very clear message to the company and to the stock market. We're 100% behind you, now go & get the job finished". You might get a small hike in share price because of the increased demand, but the bottomline is any stock issued through subscription rights effectively increases the number of shares in the market. This means that shareholder ownership is diluted as is the value of each share. I predict the share price will fall nearer 5p over the coming weeks. If there is any positive news I'd invest at that point. As I've said many times for the many reasons I posted I just can't see it. |
Posted at 01/4/2024 09:42 by peaceandlove BobblerPosts: 1,035 Price: 10.75 No Opinion RE: Lessons for Bioentrepreneurs and InvestorsToday 09:25 If SAR data from p1 is good you can see from the reports data just how undervalued this share is at the current time. Omg 😱 😆 Another deluded poster 🙄. The happy clappers are relentless. The share price is overvalued IMO. Do you know what's going on here? Massive dilution, no revenue stream, million of pounds of losses, Safety data is one thing, but does it work? Nope, sorry the share price is currently overvalued. Wait until you receive news of revenue streams. Could be waiting a longtime 😆🤣 share price will be below 5p sooner rather than later. |
Posted at 29/3/2024 07:33 by peaceandlove This is what annoys me from idiots ramping this stock 👇Brighty1 Posted in: SAR Posts: 2,504 Price: 10.75 No Opinion Back to where we were 3 years ago but....Today 07:11 The share price is back to where we were 3 years ago but the science is further forward. Some of us have made good gains on Sareum from these levels. For me it was a near x25 in my ISA and SIPP. It’s about timing. If you still believe in the science then it is highly probable that this will multiply many times from the current and quite appalling 10p level. If the data for SRA737 and SDC1801/1802 turns out to be as good as some of us think then there is still going to be good money to be made here again. It’s whether investors now have faith in TM, share price and JR to deliver. That is an enormous conundrum..... Good luck, Brighty. A total lie. The share price was at 95p new money 3 years ago as at close of business yesterday. These idiots think we're all stupid. Well you can ramp away and I will continue to call you fools out! |
Posted at 29/3/2024 07:10 by peaceandlove Good morning! Below is a post on LSE from Meg was Norma on here, before my time, but believes Wolf and I are the same person LOL. She sounds a lot like SOG LOL perhaps they are the same person? 🤔 She is also calling us 'It' how rude. 🤣MegRS300 Posts: 15 Price: 10.75 No Opinion RE: Valuation…28 Mar 2024 21:25 Some things are open to interpretation. I feel, having used it and then converted $ to E, that we’re currently worth somewhere between £86m and £117m. That involves me removing obscure outliers. LOL, she is valuing Sar at these ridiculous values when it's current market cap is less than £8million 🤦🏻 Btw SOG Sareum hasn't gone bust yet because you and the happy clappers keep on investing because you're SO blinded by the science and think a license deal will happen. Not on your Nelly sunshine. I'll tell you why again. The MHRA refused Sareum a Phase 1 CTA (Clinical Trial Authorisation) despite the fact that an external & experienced Consultancy (CRO) had developed the novel capsule technology for them. The MHRA felt that the novel formulation was not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. By going to the Australian Regulator Authority, Sareum will to use their diminishing financial resources to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b). As someone else, it's the last throw of the dice. The Clinical Trial at present, phase 1 assesses only the basic safety of the molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. Therefore, even with good safety data it means nothing really. Why are LSE continuing to delude themselves with you SOG has being Chief Ramper. PLEASE STOP! In addition to all of this, Sareum will have to further raise funds which means further dilution. More, more money will need to be raised and it'll be shareholders paying for it! So Meg (Norma) and SOG as I said stop ramping and trying to con more people to invest more into a company that clearly has a mountain to climb. The share price is down nearly 85% since January this year, the market has spoken, you both and the other happy clappers are saying disgusting things to encourage innocent people to invest in a company that is a busted flush! SOG, you should know better, grow up FFS. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
